Loss of betaglycan expression in ovarian cancer: Role in motility and invasion

Nadine Hempel, Tam How, Mei Dong, Susan K. Murphy, Timothy A. Fields, Gerard C. Blobe

Research output: Contribution to journalArticle

84 Scopus citations

Abstract

The transforming growth factor-β (TGF-β) superfamily members, TGF-β, activin, and inhibin, all have prominent roles in regulating normal ovarian function. Betaglycan, or the type III TGF-β receptor, is a coreceptor that regulates TGF-β, activin, and inhibin signaling. Here, we show that betaglycan expression is frequently decreased or lost in epithelial derived ovarian cancer at both the mRNA and protein level, with the degree of loss correlating with tumor grade. Treatment of ovarian cancer cell lines with the methyltransferase inhibitor 5-aza-2-deoxycytidine and the histone deacetylase inhibitor trichostatin A resulted in significant synergistic induction of betaglycan message levels and increased betaglycan protein expression, indicating that epigenetic silencing may play a role in the loss of betaglycan expression observed in ovarian cancer. Although restoring betaglycan expression in Ovca429 ovarian cancer cells is not sufficient to restore TGF-β-mediated inhibition of proliferation, betaglycan significantly inhibits ovarian cancer cell motility and invasiveness. Furthermore, betaglycan specifically enhances the antimigratory effects of inhibin and the ability of inhibin to repress matrix metalloproteinase levels in these cells. These results show, for the first time, epigenetic regulation of betaglycan expression in ovarian cancer, and a novel role for betaglycan in regulating ovarian cancer motility and invasiveness.

Original languageEnglish (US)
Pages (from-to)5231-5238
Number of pages8
JournalCancer Research
Volume67
Issue number11
DOIs
StatePublished - Jun 1 2007

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this